Figure 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Survival in patients with no prior systemic therapy for advanced breast cancer in the full analysis population. Kaplan–Meier curve determined in the full analysis population of (A) PFS and (B) OS. PFS was determined by the time from the date of the first dose of study drug to the date of the first radiologic documentation of postbaseline disease progression or death due to any cause. OS was defined as the time from the start of the study drug to death due to any cause.